- $12.45m
- $3.86m
- $5.21m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.28 | ||
| Price to Tang. Book | 2.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -483.25% | ||
| Return on Equity | -614.05% | ||
| Operating Margin | -628.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.22 | 4.91 | 5.82 | 5.21 | 4.21 | 20.17 | 76.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Directors
- Richard Hawkins NEC (72)
- Marc Hedrick PRE
- Andrew Sims CFO (48)
- Norman LaFrance OTH (72)
- Howard Clowes IND (67)
- Robert Lenk IND (73)
- Greg Petersen IND (58)
- Annigje Van Es-johansson IND (61)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 16th, 1997
- Public Since
- August 9th, 2000
- No. of Shareholders
- 25
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 7,589,774
- Address
- 6420 LEVIT GREEN BOULEVARD, SUITE 310, HOUSTON, 77021
- Web
- https://cerenome.com
- Phone
- +1 3026365401
- Auditors
- CBIZ CPAs P.C.
Latest News for CNSY
Upcoming Events for CNSY
Q3 2026 Cerenome, Inc. Earnings Release
Q4 2026 Cerenome, Inc. Earnings Release
Similar to CNSY
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 19:52 UTC, shares in Cerenome are trading at $1.64. This share price information is delayed by 15 minutes.
Shares in Cerenome last closed at $1.64 and the price had moved by -89.67% over the past 365 days. In terms of relative price strength the Cerenome share price has underperformed the S&P500 Index by -90.79% over the past year.
The overall consensus recommendation for Cerenome is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCerenome does not currently pay a dividend.
Cerenome does not currently pay a dividend.
Cerenome does not currently pay a dividend.
To buy shares in Cerenome you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.64, shares in Cerenome had a market capitalisation of $12.45m.
Here are the trading details for Cerenome:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CNSY
Based on an overall assessment of its quality, value and momentum Cerenome is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cerenome is $27.75. That is 1592.07% above the last closing price of $1.64.
Analysts covering Cerenome currently have a consensus Earnings Per Share (EPS) forecast of -$4.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerenome. Over the past six months, its share price has underperformed the S&P500 Index by -76.62%.
As of the last closing price of $1.64, shares in Cerenome were trading -66.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cerenome PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cerenome's management team is headed by:
- Richard Hawkins - NEC
- Marc Hedrick - PRE
- Andrew Sims - CFO
- Norman LaFrance - OTH
- Howard Clowes - IND
- Robert Lenk - IND
- Greg Petersen - IND
- Annigje Van Es-johansson - IND